Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma

Affiliations

• ¹ Skin Cancer Unit, Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genova, Italy. Electronic address: boutros.andrea@gmail.com.
• ² Skin Cancer Unit, Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genova, Italy.
• ³ Skin Cancer Unit, Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
• ⁴ Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genova, Italy; Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
• ⁵ Department of Surgical Sciences and Integrated Diagnostics (DISC), Plastic Surgery Division, University of Genoa, Genova, Italy.
• ⁶ Skin Cancer Unit, Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Surgical Sciences and Integrated Diagnostics (DISC), Plastic Surgery Division, University of Genoa, Genova, Italy.